Regulation of the PI3K-Akt network: Current status and a promise for the treatment of human diseases

Current Signal Transduction Therapy

Volumn 3, Issue 2, 2008, Pages 138-151

  Noguchi, Masayuki ^a,c   Obata, Toshiyuki ^b   Suizu, Futoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c NONE   (Japan)

Author keywords

Akt; Cancer therapy; Inhibitors; P13K Akt network; Pharmacological compounds; Phosphoinositide 3 kinase

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CELECOXIB; GLUCOSE TRANSPORTER 4; INTEGRIN LINKED KINASE; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; OSU 003012; OSU 03012; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE B BETA; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; T CELL LEUKEMIA 1 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE REGULATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SYNTHESIS; GENE TARGETING; GENE TRANSLOCATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 54949098179     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208784223189     Document Type: Review

References (152)

1. Hunter T. Signaling-2000 and beyond. Cell 2000; 100: 113-127.
2. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005; 37: 590-592.
3. Linding R, Jensen LJ, Ostheimer GJ, et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007; 129: 1415-1426.
4. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
5. Brazil DP, Park J, Hemmings BA, et al. PKB binding proteins. Getting in on the Akt. Cell 2002; 111: 293-303.
6. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
7. Du K, Tsichlis PN. Regulation of the Akt kinase by interacting proteins. Oncogene 2005; 24: 7401-7409.
8. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171.
9. Chair TO, Rittenhouse SE, Tsichlis PN, et al. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999; 68: 965-1014.
10. Fruman DA, Meyers RE, Cantley LC, et al. Phosphoinositide kinases. Annu Rev Biochem 1998; 67: 481-507.
11. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426.
12. Engelman JA, Luo J, Cantley LC, et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
13. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
14. Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just as a coactivator for Akt. FASEB J 2007; 21: 2273-2284.
15. Teitell MA. The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer 2005; 5: 640-648.
16. Lock RB. TCL1: a new drug target in lymphoid and germ-cell malignancies? Int J Biochem Cell Biol 2003; 35: 1614-1618.
17. Luo J, Manning BD, Cantley LC, et al. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-262.
18. Gillooly DJ, Morrow IC, Lindsay M, et al. Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. EMBO J 2000; 19: 4577-4588.
19. McMullen JR, Jay PY. PI3K (p110alpha) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 2007; 6: 910-913.
20. Fan QW, Weiss WA. Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 2006; 5: 2301-2305.
21. Yu K, Lucas J, Zhu T, et al. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 2005; 4: 538-545.
22. Francois F, Klotman ME. Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. J Virol 2003; 77: 2539-2549.
23. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003; 278: 3694-3704.
24. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
25. Chung TW, Lee YC, Kim CH et al. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-1125.
26. Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans 2007; 35: 204-206.
27. Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/ reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 19866-19871.
28. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22: 183-198.
29. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245.
30. Lian Z, Di Cristofano A. Class reunion: PTEN joins the nuclear crew. Oncogene 2005; 24: 7394-7400.
31. Rosivatz E. Inhibiting PTEN. Biochem Soc Trans 2007; 35: 257-259.
32. Srivastava AK, Mehdi MZ. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 2005; 22: 2-13.
33. Sasaoka T, Wada T, Tsuneki H, et al. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 2006; 112: 799-809.
34. Lazar DF, Saltiel AR. Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov 2006; 5: 333-342.
35. Thomas CC, Deak M, Alessi DR, van Aalten DM. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 2002; 12: 1256-1262.
36. Auguin D, Barthe P, Royer C, et al. Structural Basis for the Co-activation of Protein Kinase B by T-cell Leukemia-1 (TCL1) Family Proto-oncoproteins. J Biol Chem 2004; 279: 35890-35902.
37. Auguin D, Barthe P, Auge-Senegas MT, et al. Solution Structure and Back-bone Dynamics of the Pleckstrin Homology Domain of the Human Protein Kinase B (PKB/Akt). Interaction with Inositol Phosphates. J Biomol NMR 2004; 28: 137-155.
38. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate pbosphatidylinositol 3,4,5- trisphosphate-dependent activation of protein kinase B. Science 1998; 279: 710-714.
39. Storz P, Toker A. 3′-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci 2002; 7: d886-902.
40. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-2624.
41. Sato S, Fujita N, Tsuruo T, et al. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21: 1727-1738.
42. Hotte SJ, Oza A, Winquist EW, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006; 17: 334-340.
43. Yacoub A, Park MA, Hanna D, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells, Mol Pharmacol 2006; 70: 589-603.
44. Tseng PH, Lin HP, Zhu J, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005; 105: 4021-4027.
45. McCubrey JA, Lahair MM, Franklin RA, et al. OSU-03012 in the treatment of glioblastoma. Mol Pharmacol 2006; 70: 437-439.
46. Zeng Z, Samudio IJ, Zhang W, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006; 66: 3737-3746.
47. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 2004; 279: 47720-47725.
48. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
49. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004; 279: 41189-41196.
50. Hannigan G, Troussard AA, Dedhar S, et al. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51-63.
51. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 2001; 114: 1125-1136.
52. Oloumi A, Syam S, Dedhar S, et al. Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene 2006; 25: 7747-7757.
53. Acconcia F, Manavathi B, Mascarenhas J, et al. An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. Cancer Res 2006; 66: 11030-11038.
54. Dong LQ, Liu F. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab 2005; 289: E187-196.
55. Delcommenne M, Tan C, Gray V, et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked krinase. Proc Natl Acad Sci USA 1998; 95: 11211-11216.
56. Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999; 9: 393-404.
57. Dixelius J, Olsson AK, Thulin A, et al. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res 2006; 66: 2089-2097.
58. Liu J, Costello PC, Pham NA, et al. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J Thorac Oncol 2006; 1: 771-779.
59. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97: 3207-3212.
60. Edwards LA, Thiessen B, Dragowska WH, et al. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 2005; 24: 3596-3605.
61. Trotman LC, Alimonti A, Scaglioni PP, et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441: 523-527.
62. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404: 782-787.
63. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-1152.
64. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27 (Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136-1144.
65. Kandel ES, Skeen J, Majewski N, et al. Activation of Akt/protein kinase B overcomes a G(2)/in cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002; 22: 7831-7841.
66. Katayama K, Fujila N, Tsuruo T, et al. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol 2005; 25: 5725-5737.
67. Cross DA, Alessi DR, Cohen P, et al. Andjelkovich, M., and Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
68. Whiteman EL, Cho H, Birnbaum MJ, et al. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002; 13: 444-451.
69. Boxer RB, Stairs DB, Dugan KD, et al. Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab 2006; 4: 475-490.
70. Sano H, Kane S, Sano E, et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003; 278: 14599-14602.
71. Dugani CB, Klip A. Glucose transporter 4: cycling, compartments and controversies. EMBO Rep 2005; 6: 1137-1142.
72. Ishikura S, Bilan PJ, Klip A, et al. Rabs 8A and 14 are targets of the insulin-regulated Rab-GAP AS160 regulating GLUT4 traffic in muscle cells. Biochem Biophys Res Commun 2007; 353: 1074-1079.
73. Roach WG, Chavez JA, Miinea CP, Lienhard GE. Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. Biochem J 2007; 403: 353-358.
74. Sano H, Eguez L, Teruel MN, et al. Rab10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab, 2007; 5: 293-303.
75. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996; 399: 333-338.
76. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224.
77. Kimura A, Ohmichi M, Kawagoe J, et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004; 23: 4505-4515.
78. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
79. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
80. Birnbaum MJ. On the InterAktion between hexokinase and the mitochondrion. Dev Cell 2004; 7: 781-782.
81. Lu Y, Wang H, Mills GB, et al. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003; 7: 205-228.
82. Mills GB, Kohn E, Lu Y, et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003; 30: 93-104.
83. Reuveni H, Livnah N, Geiger T, et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002; 41: 10304-10314.
84. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005; 24: 7493-7501.
85. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64: 4394-4399.
86. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
87. Hu Y, Qiao L, Wang S, et al. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem. 2000; 43: 3045-3051.
88. Gills JJ, Holbeck S, Hollingshead, et al. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther 2006; 5: 713-722.
89. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003; 89: 1-5.
90. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24: 7435-7442.
91. Yoeli-Lerner M, Yiu GK, Rabinovitz I, et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005; 20: 539-550.
92. Irie HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005; 171: 1023-1034.
93. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006; 66: 3963-3966.
94. Stambolic V, Woodgett JR. Functional distinctions of protein kinase B/ Akt isoforms defined by their influence on cell migration. Trends Cell Biol 2006; 16: 461-466.
95. DeFeo-Jones D, Barnett SF, Fu S, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005; 4: 271-279.
96. Katome T, Obata T, Matsushima R., et al. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem 2003; 278: 28312-28323.
97. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64: 7002-7010.
98. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl- myoinositol analogues. Mol Cancer Ther 2003; 2: 389-399.
99. Zhang M, Fang X, Liu H, et al. Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells. Cancer Lett 2007; 252: 244-258.
100. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCLI gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530-12534.
101. Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/ delta locus in mature T cell proliferations. Oncogene 1993; 8: 2475-2483.
102. Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 1999; 96: 2949-2951.
103. Hoh F, Yang YS, Guignard L, et al. Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. Structure 1998; 6: 147-155.
104. MTCP1. J Biomol NMR 1998; 11: 339-356.
105. Teitell M, Damore MA, Sulur GG, et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci USA 1999; 96: 9809-9814.
106. Pekarsky Y, Hallas C, Croce CM, et al. Molecular basis of mature T-cell leukemia. JAMA 2001; 286: 2308-2314.
107. Galan-Caridad JM, Harel S, Arenzana TL, el al. Zfx controls the self-renewal of embryonic and hematopoietic stem cells. Cell 2007; 129: 345-357.
108. Ivanova N, Dobrin R, Lu R., Kotenko I. Dissecting self-renewal in stem cells with RNA interference. Nature 2006; 442: 533-538.
109. Hiromura M, Okada F, Obata T, et al. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. J Biol Chem 2004; 279: 53407-53418.
110. Rong SB, Hu Y, Enyedy I, et al. Molecular modeling studies of the Akt PH domain and its interaction with phosphomositides. J Med Chem 2001; 44: 898-908.
111. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 2003; 125: 1144-1145.
112. Barnett SF, Defeo-Jones D. Fu S, et al. Identification and characterization of pleckstrin-homology- domain- dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005; 385: 399-408.
113. Lemmon MA, Ferguson KM. Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem J 2000; 350 (Pt 1): 1-18.
114. Maira SM, Galetic I, Brazil DP, et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001; 294: 374-380.
115. Sato S, Fujita N, Tsuruo T, et al. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-10837.
116. Blagg BS, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 2006; 26: 310-338.
117. Kim AH, Yano H, Cho H, et al. Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron 2002; 35: 697-709.
118. Jahn T, Seipel P, Urschel S, Peschel C, Duyster J. Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol 2002; 22: 979-991.
119. Yue Y, Lypowy J, Hedhli N, Abdellatif M. Ras GTPase-activating protein binds to Akt and is required for its activation. J Biol Chem 2004; 279: 12883-12889.
120. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510.
121. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10: 151-162.
122. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 2003; 31: 573-578.
123. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259-1268.
124. Tee AR, Anjum R, Blenis J, et al. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 2003; 278: 37288-37296.
125. Han EK, Leverson JD, McGonigal T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007; 26: 5655-5661.
126. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537.
127. Ikezoe T, Nishioka C, Bandobashi K, et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2007; 31: 673-682.
128. Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/ mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006; 7: 285-294.
129. Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther 2005; 314: 1134-1143.
130. Ohji G, Hidayat S, Nakashima A, et al. Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin. J Biochem (Tokyo) 2006; 139: 129-135.
131. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21: 1159-1166.
132. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003-4009.
133. Zhou GL, Tucker DF, Bae SS, et al. Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. J Biol Chem 2006; 281: 36443-36453.
134. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005; 56: 47-60.
135. Marmy-Conus N, Hannan KM, Pearson RB, et al. Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling. FEBS Lett 2002; 519: 135-140.
136. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
137. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2095; 65: 7052-7058.
138. Manning BD, Logsdon MN, Lipovsky AI, et al. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 2005; 19: 1773-1778.
139. Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63: 2172-2178.
140. Brazil DP, Yang ZZ, Hemmings BA, et al. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-242.
141. Yang ZZ, Tschopp O, Baudry A, et al. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004; 32: 350-354.
142. Barr RK, Boehm I, Attwood PV, Watt PM, Bogoyevitch MA. The Critical Features and the Mechanism of Inhibition of a Kinase Interaction Motif-based Peptide Inhibitor of JNK. J Biol Chem 2004; 279: 36327-36338.
143. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001; 61: 1768-1775.
144. Niv MY, Rubin H, Cohen J, et al. Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J Biol Chem 2004; 279: 1242-1255.
145. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005; 24: 7482-7492.
146. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22: 4217-4226.
147. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
148. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
149. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003; 300: 1574-1577.
150. Mitsuuchi Y, Johnson SW, Sonoda G, et al. Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene 1999; 18: 4891-4898.
151. Paramio JM, Segrelles C, Ruiz S, Jorcano JL. Inhibition of protein kinase B (PKB) and PKCzeta mediates keratin K10-induced cell cycle arrest. Mol Cell Biol 2001; 21: 7449-7459.
152. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36: 131-137.